Sandbox Reserved 1474: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Christina R. Bourne, Zhaihui G. Modlin

Revision as of 11:02, 10 December 2018 view source Zhaihui G. Modlin (talk \| contribs) 255 edits No edit summary ← Older edit		Revision as of 11:05, 10 December 2018 view source Zhaihui G. Modlin (talk \| contribs) 255 edits No edit summary Newer edit →
Line 67:		Line 67:
	Screening for anti(+)METH IgG response was conducted by radioimmunoassay (RIA)<ref name="Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse"/> in which radio labelled [(+)-3H] METH is competing with unlabelled (+)-METH and (+)-AMP for the binding site of Abs in a manner similar to what has been previously described<ref name ="Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor"/>. An IC50 value was determined for each compound after fitting a sigmoidal curve to the data points<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/><ref name="Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse"/>.		Screening for anti(+)METH IgG response was conducted by radioimmunoassay (RIA)<ref name="Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse"/> in which radio labelled [(+)-3H] METH is competing with unlabelled (+)-METH and (+)-AMP for the binding site of Abs in a manner similar to what has been previously described<ref name ="Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor"/>. An IC50 value was determined for each compound after fitting a sigmoidal curve to the data points<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/><ref name="Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse"/>.

	Anti-(+)METH mAb6H4 was reported with Kd = 11 nM<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats/>, having <.01% cross-reactivity with almost all compounds tested (including (-)-METH, (+/-)-AMP,(+/-)-MDMA,4-OH METH, Pseudoephedrine, Ephedrine, Dopamine, Norepinephrine, Serotonin, Epinephrine)<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats/> except for (+)-methylenedioxymethamphetamine (MDMA) which has just slightly higher relative affinity than METH (9 nM to 11nM)<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats/>. It was also stereospecific, having an approximately 100 times higher relative affinity for the plus form than the minus forms of these substances. no significant cross activity has been observed in the test for other compounds including methylenedioxyamphetamine, (+)-norpseudoephedrine, L-phenylephrine, (+)-phenylpropanolamine, beta-phenylethylamine, and tyramine<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats/>.		Anti-(+)METH mAb6H4 was reported with Kd = 11 nM<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/>, having <.01% cross-reactivity with almost all compounds tested (including (-)-METH, (+/-)-AMP,(+/-)-MDMA,4-OH METH, Pseudoephedrine, Ephedrine, Dopamine, Norepinephrine, Serotonin, Epinephrine)<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/> except for (+)-methylenedioxymethamphetamine (MDMA) which has just slightly higher relative affinity than METH (9 nM to 11nM)<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/>. It was also reported stereospecific<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/>, having an approximately 100 times higher relative affinity for the plus form than the minus forms of these substances<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/>. No significant cross activity has been observed in the test for other compounds<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/> including methylenedioxyamphetamine, (+)-norpseudoephedrine, L-phenylephrine, (+)-phenylpropanolamine, beta-phenylethylamine, and tyramine<ref name="Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats"/>.